Natco Pharma has increased its investment in US-based biotech firm eGenesis to $16.7 million via convertible notes. This brings the company's total commitment to $24.7 million, marking a strategic push into advanced biotechnology research beyond its traditional generic drug business.
Natco Pharma is deepening its financial involvement in the US-based biotechnology company eGenesis. The Hyderabad-based pharmaceutical firm has announced an increase in its planned investment to $16.7 million, rising from a previously declared $14 million. This capital injection is being distributed through the company's international subsidiaries, with Natco Pharma Canada contributing $13.7 million and Natco Pharma USA providing the remaining $3 million.
The investment is structured as a purchase of convertible promissory notes, which carry an 8% annual compounded interest rate. This arrangement means that Natco Pharma does not gain immediate additional equity in eGenesis, but the notes offer the potential for future conversion, providing a debt-based return in the interim. The company expects the transaction to be completed by October 31, 2026. Following this finalization, Natco’s aggregate investment in eGenesis will reach $24.7 million when combined with capital deployed earlier in the year.
Traditionally recognized for its strong portfolio in complex generic pharmaceuticals, particularly in the oncology and specialty drug segments, this move indicates a broader strategic shift for Natco. By funding early-stage biotech research, the company is aiming to expand its presence into higher-value, innovation-led therapeutic areas. This diversification is a common strategy for pharmaceutical firms looking to reduce their reliance on the highly competitive and price-sensitive global generic market, where profit margins can often face pressure.
Investors should consider that the biotechnology sector carries inherent risks, primarily related to long research and development timelines and the uncertainty of therapeutic outcomes. Unlike the manufacturing-focused business of generics, biotech innovation involves a higher degree of technical risk. As the company expands its footprint in this space, market participants will likely look for updates regarding the specific therapeutic programs funded by this capital and the progress of the R&D pipeline. The company's ability to balance its established core generic operations with these high-risk, high-reward international investments will remain a key factor for shareholders to track.